Island Pharmaceuticals Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Island Pharmaceuticals's earnings have been declining at an average annual rate of -17.2%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been growing at an average rate of 137.8% per year.
Información clave
-17.2%
Tasa de crecimiento de los beneficios
28.9%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 31.2% |
| Tasa de crecimiento de los ingresos | 137.8% |
| Rentabilidad financiera | -188.6% |
| Margen neto | -228.9% |
| Última actualización de beneficios | 30 Jun 2024 |
Actualizaciones de resultados anteriores recientes
No hay actualizaciones
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero Island Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -3 | 2 | 0 |
| 31 Mar 24 | 1 | -3 | 2 | 0 |
| 31 Dec 23 | 1 | -2 | 2 | 1 |
| 30 Sep 23 | 0 | -3 | 2 | 1 |
| 30 Jun 23 | 0 | -3 | 2 | 0 |
| 31 Mar 23 | 0 | -3 | 2 | 0 |
| 31 Dec 22 | 0 | -3 | 2 | 1 |
| 30 Sep 22 | 0 | -3 | 2 | 1 |
| 30 Jun 22 | 0 | -3 | 2 | 1 |
| 31 Mar 22 | 0 | -3 | 2 | 1 |
| 31 Dec 21 | 0 | -3 | 3 | 0 |
| 30 Sep 21 | 0 | -3 | 2 | 0 |
| 30 Jun 21 | 0 | -2 | 2 | 0 |
| 30 Jun 20 | 0 | 0 | 0 | 0 |
| 31 Dec 19 | 0 | -1 | 0 | 1 |
Ingresos de calidad: ILA is currently unprofitable.
Margen de beneficios creciente: ILA is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: ILA is unprofitable, and losses have increased over the past 5 years at a rate of 17.2% per year.
Acelerando crecimiento: Unable to compare ILA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: ILA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).
Rentabilidad financiera
Alta ROE: ILA has a negative Return on Equity (-188.59%), as it is currently unprofitable.